GoodRx Holdings, Inc. (NASDAQ:GDRX) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET

Company Participants

Whitney Notaro - Vice President, Investor Relations

Doug Hirsch - Co-Founder & Co-Chief Executive Officer

Trevor Bezdek - Co-Founder Co-Chief Executive Officer,

Karsten Voermann - Chief Financial Officer

Conference Call Participants

Justin Post - Bank of America

John Ransom - Raymond James

Mark Mahaney - Evercore

George Hill - Deutsche Bank

Sean Dodge - RBC Capital Markets

Sandy Draper - Guggenheim

Charles Rhyee - Cowen

Ricky Goldwasser - Morgan Stanley

Glen Santangelo - Jefferies

Stephanie Davis - SVB

Doug Anmuth – JPMorgan

Steven Valiquette - Barclays

Jonathan Yong - Credit Suisse

Stan Berenshteyn - Wells Fargo

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx First Quarter 2022 Earnings Call. At this time -- as a reminder, today's conference call is being recorded.

I would now like to introduce your host for today's call, Whitney Notaro, Vice President of Investor Relations. Ms. Notaro, you may begin.

Whitney Notaro

Thank you, operator. Good afternoon, everyone, and welcome to GoodRx's earnings conference call for the first quarter of 2022. Joining me today are Doug Hirsch and Trevor Bezdek, our Co-Founders and Co-Chief Executive Officer; and Karsten Voermann, our Chief Financial Officer.

Before we begin, I'd like to remind everyone that this call will contain forward-looking statements. All statements made on this call that do not relate to matters of historical facts should be considered forward-looking statements, including statements regarding management's plans, strategies, goals and objectives, our market opportunity, our anticipated financial performance and the expected impact of COVID-19 on our business.

These statements are neither promises, nor guarantees, but involve known and unknown risks, uncertainties and other important factors. These factors may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Factors discussed in the Risk Factors section of our quarterly report on Form 10-Q for the quarter ended March 31, 2022 and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made on this call.

Any such forward-looking statements represent management's estimates as of the date of this call, and we disclaim any obligation to update these statements, even if subsequent events cause our views to change.

In addition, we may also reference certain non-GAAP metrics, which are reconciled to the nearest GAAP metric in the company's shareholder letter, which can be found on the overview page of our Investor Relations website at investors.goodrx.com.